Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Clostridium difficile ribotype 027 is most prevalent among inpatients admitted from long-term care facilities.

Archbald-Pannone LR, Boone JH, Carman RJ, Lyerly DM, Guerrant RL.

J Hosp Infect. 2014 Dec;88(4):218-21. doi: 10.1016/j.jhin.2014.06.016. Epub 2014 Jul 30.

2.

Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality.

Boone JH, Archbald-Pannone LR, Wickham KN, Carman RJ, Guerrant RL, Franck CT, Lyerly DM.

Eur J Clin Microbiol Infect Dis. 2014 Jun;33(6):1045-51. doi: 10.1007/s10096-013-2043-1. Epub 2014 Jan 22.

3.

Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection.

Boone JH, DiPersio JR, Tan MJ, Salstrom SJ, Wickham KN, Carman RJ, Totty HR, Albert RE, Lyerly DM.

Eur J Clin Microbiol Infect Dis. 2013 Dec;32(12):1517-23. doi: 10.1007/s10096-013-1905-x. Epub 2013 Jun 18.

4.

Glutamate dehydrogenase is highly conserved among Clostridium difficile ribotypes.

Carman RJ, Wickham KN, Chen L, Lawrence AM, Boone JH, Wilkins TD, Kerkering TM, Lyerly DM.

J Clin Microbiol. 2012 Apr;50(4):1425-6. doi: 10.1128/JCM.05600-11. Epub 2012 Feb 1.

5.

Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency.

Boone JH, Goodykoontz M, Rhodes SJ, Price K, Smith J, Gearhart KN, Carman RJ, Kerkering TM, Wilkins TD, Lyerly DM.

Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1551-9. doi: 10.1007/s10096-011-1477-6. Epub 2011 Dec 14.

PMID:
22167256
6.

CD4+ and CD8+ T cell- and IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine.

Guo X, Barroso L, Lyerly DM, Petri WA Jr, Houpt ER.

Vaccine. 2011 Jan 17;29(4):772-7. doi: 10.1016/j.vaccine.2010.11.013. Epub 2010 Nov 21.

7.

Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea.

Carman RJ, Genheimer CW, Rafii F, Park M, Hiltonsmith MF, Lyerly DM.

Anaerobe. 2009 Dec;15(6):244-8. doi: 10.1016/j.anaerobe.2009.09.009. Epub 2009 Oct 8.

PMID:
19818865
8.

Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon.

Guo X, Barroso L, Becker SM, Lyerly DM, Vedvick TS, Reed SG, Petri WA Jr, Houpt ER.

Infect Immun. 2009 Sep;77(9):3909-18. doi: 10.1128/IAI.00487-09. Epub 2009 Jun 29.

9.

Molecular characterization and antimicrobial susceptibilities of extra-intestinal Clostridium difficile isolates.

Zheng L, Citron DM, Genheimer CW, Sigmon SF, Carman RJ, Lyerly DM, Goldstein EJ.

Anaerobe. 2007 Jun-Aug;13(3-4):114-20. Epub 2007 Apr 11.

PMID:
17531516
10.

Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease.

Walker TR, Land ML, Kartashov A, Saslowsky TM, Lyerly DM, Boone JH, Rufo PA.

J Pediatr Gastroenterol Nutr. 2007 Apr;44(4):414-22.

PMID:
17414136
11.

Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters.

Geric B, Carman RJ, Rupnik M, Genheimer CW, Sambol SP, Lyerly DM, Gerding DN, Johnson S.

J Infect Dis. 2006 Apr 15;193(8):1143-50. Epub 2006 Mar 6.

PMID:
16544255
12.

Revised nomenclature of Clostridium difficile toxins and associated genes.

Rupnik M, Dupuy B, Fairweather NF, Gerding DN, Johnson S, Just I, Lyerly DM, Popoff MR, Rood JI, Sonenshein AL, Thelestam M, Wren BW, Wilkins TD, von Eichel-Streiber C.

J Med Microbiol. 2005 Feb;54(Pt 2):113-7.

PMID:
15673503
13.

Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens.

Zheng L, Keller SF, Lyerly DM, Carman RJ, Genheimer CW, Gleaves CA, Kohlhepp SJ, Young S, Perez S, Ye K.

J Clin Microbiol. 2004 Aug;42(8):3837-40.

14.

Clostridium difficile testing: after 20 years, still challenging.

Wilkins TD, Lyerly DM.

J Clin Microbiol. 2003 Feb;41(2):531-4. Review. No abstract available.

15.

Genetic characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates by PCR.

Moncrief JS, Zheng L, Neville LM, Lyerly DM.

J Clin Microbiol. 2000 Aug;38(8):3072-5.

17.

Deletions in the repeating sequences of the toxin A gene of toxin A-negative, toxin B-positive Clostridium difficile strains.

Kato H, Kato N, Katow S, Maegawa T, Nakamura S, Lyerly DM.

FEMS Microbiol Lett. 1999 Jun 15;175(2):197-203.

18.

TechLab and alexon Giardia enzyme-linked immunosorbent assay kits detect cyst wall protein 1.

Boone JH, Wilkins TD, Nash TE, Brandon JE, Macias EA, Jerris RC, Lyerly DM.

J Clin Microbiol. 1999 Mar;37(3):611-4.

19.

Infection and immunity mediated by the carbohydrate recognition domain of the Entamoeba histolytica Gal/GalNAc lectin.

Dodson JM, Lenkowski PW Jr, Eubanks AC, Jackson TF, Napodano J, Lyerly DM, Lockhart LA, Mann BJ, Petri WA Jr.

J Infect Dis. 1999 Feb;179(2):460-6.

PMID:
9878032
20.

Intestinal secretory factor released by macrophages stimulated with Clostridium difficile toxin A: role of interleukin 1beta.

Rocha MF, Soares AM, Flores CA, Steiner TS, Lyerly DM, Guerrant RL, Ribeiro RA, Lima AA.

Infect Immun. 1998 Oct;66(10):4910-6.

21.

Comparison of restriction enzyme analysis, arbitrarily primed PCR, and protein profile analysis typing for epidemiologic investigation of an ongoing Clostridium difficile outbreak.

Rafferty ME, Baltch AL, Smith RP, Bopp LH, Rheal C, Tenover FC, Killgore GE, Lyerly DM, Wilkins TD, Schoonmaker DJ, Hannett GE, Shayegani M.

J Clin Microbiol. 1998 Oct;36(10):2957-63.

22.

Multicenter evaluation of the Clostridium difficile TOX A/B TEST.

Lyerly DM, Neville LM, Evans DT, Fill J, Allen S, Greene W, Sautter R, Hnatuck P, Torpey DJ, Schwalbe R.

J Clin Microbiol. 1998 Jan;36(1):184-90.

23.
24.
25.

Role of tumor necrosis factor and nitric oxide in the cytotoxic effects of Clostridium difficile toxin A and toxin B on macrophages.

Melo Filho AA, Souza MH, Lyerly DM, Cunha FQ, Lima AA, Ribeiro RA.

Toxicon. 1997 May;35(5):743-52.

PMID:
9203299
26.

Role of bacterial metabolism and physiology in the pathogenesis of Clostridium difficile disease.

Bongaerts GP, Lyerly DM.

Microb Pathog. 1997 Apr;22(4):253-6. No abstract available.

PMID:
9140922
27.

Transcriptional analysis of the toxigenic element of Clostridium difficile.

Hammond GA, Lyerly DM, Johnson JL.

Microb Pathog. 1997 Mar;22(3):143-54.

PMID:
9075217
28.

Entamoeba histolytica and Entamoeba dispar infection in children in Bangladesh.

Haque R, Faruque AS, Hahn P, Lyerly DM, Petri WA Jr.

J Infect Dis. 1997 Mar;175(3):734-6.

PMID:
9041357
29.

Effects of Clostridium difficile toxin A and toxin B on phospholipase D activation in human promyelocytic leukemic HL60 cells.

Ohguchi K, Banno Y, Nakashima S, Kato N, Watanabe K, Lyerly DM, Nozawa Y.

Infect Immun. 1996 Nov;64(11):4433-7.

30.

Effect of Clostridium difficile toxin B on IgE receptor-mediated signal transduction in rat basophilic leukemia cells: inhibition of phospholipase D activation.

Ojio K, Banno Y, Nakashima S, Kato N, Watanabe K, Lyerly DM, Miyata H, Nozawa Y.

Biochem Biophys Res Commun. 1996 Jul 16;224(2):591-6.

PMID:
8702431
31.

Clostridium difficile toxins attack Rho.

Wilkins TD, Lyerly DM.

Trends Microbiol. 1996 Feb;4(2):49-51. Review. No abstract available.

PMID:
8820565
32.

Effects of anti-inflammatory drugs on fever and neutrophilia induced by Clostridium difficile toxin B.

Cardoso RA, Filho AA, Melo MC, Lyerly DM, Wilkins TD, Lima AA, Ribeiro RA, Souza GE.

Mediators Inflamm. 1996;5(3):183-7.

33.
34.

Proteolytic activity of the Bacteroides fragilis enterotoxin causes fluid secretion and intestinal damage in vivo.

Obiso RJ Jr, Lyerly DM, Van Tassell RL, Wilkins TD.

Infect Immun. 1995 Oct;63(10):3820-6.

35.

The enterotoxin of Bacteroides fragilis is a metalloprotease.

Moncrief JS, Obiso R Jr, Barroso LA, Kling JJ, Wright RL, Van Tassell RL, Lyerly DM, Wilkins TD.

Infect Immun. 1995 Jan;63(1):175-81.

36.

Characterization of enterotoxigenic Bacteroides fragilis by a toxin-specific enzyme-linked immunosorbent assay.

Van Tassell RL, Lyerly DM, Wilkins TD.

Clin Diagn Lab Immunol. 1994 Sep;1(5):578-84.

37.

Tox-A Test for Clostridium difficile.

Wilkins TD, Lyerly DM.

J Clin Microbiol. 1994 Sep;32(9):2338. No abstract available.

38.
39.

Role of toxins A and B in the pathogenesis of Clostridium difficile disease.

Bongaerts GP, Lyerly DM.

Microb Pathog. 1994 Jul;17(1):1-12. Review. No abstract available.

PMID:
7861949
40.

Mutagenesis of the Clostridium difficile toxin B gene and effect on cytotoxic activity.

Barroso LA, Moncrief JS, Lyerly DM, Wilkins TD.

Microb Pathog. 1994 Apr;16(4):297-303.

PMID:
7968458
41.

Vascular and glomerular effects of Clostridium difficile toxin A peptide on the isolated rat kidney.

Monteiro HS, Santos-Neto MS, Oliveira AV, Lima AA, Lyerly DM, Fonteles MC.

Braz J Med Biol Res. 1994 Mar;27(3):743-8.

PMID:
8081300
42.

Purification and characterization of alpha-toxin produced by Clostridium novyi type A.

Ball DW, Van Tassell RL, Roberts MD, Hahn PE, Lyerly DM, Wilkins TD.

Infect Immun. 1993 Jul;61(7):2912-8.

43.

Neonatal Clostridium sordellii toxic omphalitis.

Adamkiewicz TV, Goodman D, Burke B, Lyerly DM, Goswitz J, Ferrieri P.

Pediatr Infect Dis J. 1993 Mar;12(3):253-7. Review. No abstract available.

PMID:
8451108
44.

Production of monoclonal antibodies against Clostridium difficile cytotoxin using immunosorbent binding bioassay procedure.

Depitre C, L'Haridon RM, Lyerly DM, Barroso LA, Wilkins TD, Andremont A, Corthier G.

Toxicon. 1993 Feb;31(2):181-6.

PMID:
8456445
45.

Purification and characterization of Clostridium difficile glutamate dehydrogenase.

Anderson BM, Anderson CD, Van Tassell RL, Lyerly DM, Wilkins TD.

Arch Biochem Biophys. 1993 Jan;300(1):483-8.

PMID:
8424683
46.

Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile.

Lyerly DM, Barroso LA, Wilkins TD, Depitre C, Corthier G.

Infect Immun. 1992 Nov;60(11):4633-9.

47.

Cytotoxicity of Clostridium difficile toxin A for human colonic and pancreatic carcinoma cell lines.

Kushnaryov VM, Redlich PN, Sedmak JJ, Lyerly DM, Wilkins TD, Grossberg SE.

Cancer Res. 1992 Sep 15;52(18):5096-9.

48.

Purification and characterization of an enterotoxin from Bacteroides fragilis.

Van Tassell RL, Lyerly DM, Wilkins TD.

Infect Immun. 1992 Apr;60(4):1343-50.

49.

Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase.

Lyerly DM, Barroso LA, Wilkins TD.

J Clin Microbiol. 1991 Nov;29(11):2639-42.

50.

Supplemental Content

Loading ...
Support Center